| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10220517 | Journal of Thoracic Oncology | 2018 | 9 Pages |
Abstract
Brigatinib has limited clinical activity in alectinib-refractory ALK-positive NSCLC. Additional studies are needed to establish biomarkers of response to brigatinib and to identify effective therapeutic options for alectinib-resistant ALK-positive NSCLC patients.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Jessica J. MD, Viola W. MD, PhD, Adam J. MD, Beow Y. ScD, Ashish MD, PhD, Lorin A. BA, Ibiayi MD, Anna F. MD, PhD, Angela MD, Anne MD, Smitha MD, Justin F. MD, Jochen K. MD, PhD, Andrew J. MD, Subba R. MD, Sai-Hong Ignatius MD, PhD, Alice T. MD, PhD,